SLRX Relative Valuation
SLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLRX is overvalued; if below, it's undervalued.
Historical Valuation
Salarius Pharmaceuticals Inc (SLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.97. The fair price of Salarius Pharmaceuticals Inc (SLRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.84
Fair
-0.00
PE
1Y
3Y
5Y
0.02
EV/EBITDA
Salarius Pharmaceuticals Inc. (SLRX) has a current EV/EBITDA of 0.02. The 5-year average EV/EBITDA is -0.12. The thresholds are as follows: Strongly Undervalued below -1.66, Undervalued between -1.66 and -0.89, Fairly Valued between 0.65 and -0.89, Overvalued between 0.65 and 1.42, and Strongly Overvalued above 1.42. The current Forward EV/EBITDA of 0.02 falls within the Historic Trend Line -Fairly Valued range.
0.03
EV/EBIT
Salarius Pharmaceuticals Inc. (SLRX) has a current EV/EBIT of 0.03. The 5-year average EV/EBIT is -0.20. The thresholds are as follows: Strongly Undervalued below -2.35, Undervalued between -2.35 and -1.27, Fairly Valued between 0.88 and -1.27, Overvalued between 0.88 and 1.95, and Strongly Overvalued above 1.95. The current Forward EV/EBIT of 0.03 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Salarius Pharmaceuticals Inc. (SLRX) has a current PS of 0.00. The 5-year average PS is 7.36. The thresholds are as follows: Strongly Undervalued below -39.47, Undervalued between -39.47 and -16.06, Fairly Valued between 30.77 and -16.06, Overvalued between 30.77 and 54.18, and Strongly Overvalued above 54.18. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
1.86
P/OCF
Salarius Pharmaceuticals Inc. (SLRX) has a current P/OCF of 1.86. The 5-year average P/OCF is -0.14. The thresholds are as follows: Strongly Undervalued below -3.47, Undervalued between -3.47 and -1.81, Fairly Valued between 1.53 and -1.81, Overvalued between 1.53 and 3.20, and Strongly Overvalued above 3.20. The current Forward P/OCF of 1.86 falls within the Overvalued range.
-0.19
P/FCF
Salarius Pharmaceuticals Inc. (SLRX) has a current P/FCF of -0.19. The 5-year average P/FCF is -0.49. The thresholds are as follows: Strongly Undervalued below -2.45, Undervalued between -2.45 and -1.47, Fairly Valued between 0.50 and -1.47, Overvalued between 0.50 and 1.48, and Strongly Overvalued above 1.48. The current Forward P/FCF of -0.19 falls within the Historic Trend Line -Fairly Valued range.
Salarius Pharmaceuticals Inc (SLRX) has a current Price-to-Book (P/B) ratio of 0.14. Compared to its 3-year average P/B ratio of 2.29 , the current P/B ratio is approximately -93.66% higher. Relative to its 5-year average P/B ratio of 1.66, the current P/B ratio is about -91.27% higher. Salarius Pharmaceuticals Inc (SLRX) has a Forward Free Cash Flow (FCF) yield of approximately -106.50%. Compared to its 3-year average FCF yield of -390.19%, the current FCF yield is approximately -72.70% lower. Relative to its 5-year average FCF yield of -266.61% , the current FCF yield is about -60.05% lower.
0.14
P/B
Median3y
2.29
Median5y
1.66
-106.50
FCF Yield
Median3y
-390.19
Median5y
-266.61
Competitors Valuation Multiple
The average P/S ratio for SLRX's competitors is 5.13, providing a benchmark for relative valuation. Salarius Pharmaceuticals Inc Corp (SLRX) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SLRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SLRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Salarius Pharmaceuticals Inc (SLRX) currently overvalued or undervalued?
Salarius Pharmaceuticals Inc (SLRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.97. The fair price of Salarius Pharmaceuticals Inc (SLRX) is between NaN to NaN according to relative valuation methord.
What is Salarius Pharmaceuticals Inc (SLRX) fair value?
SLRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Salarius Pharmaceuticals Inc (SLRX) is between NaN to NaN according to relative valuation methord.
How does SLRX's valuation metrics compare to the industry average?
The average P/S ratio for SLRX's competitors is 5.13, providing a benchmark for relative valuation. Salarius Pharmaceuticals Inc Corp (SLRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Salarius Pharmaceuticals Inc (SLRX) as of Jan 08 2026?
As of Jan 08 2026, Salarius Pharmaceuticals Inc (SLRX) has a P/B ratio of 0.14. This indicates that the market values SLRX at 0.14 times its book value.
What is the current FCF Yield for Salarius Pharmaceuticals Inc (SLRX) as of Jan 08 2026?
As of Jan 08 2026, Salarius Pharmaceuticals Inc (SLRX) has a FCF Yield of -106.50%. This means that for every dollar of Salarius Pharmaceuticals Inc’s market capitalization, the company generates -106.50 cents in free cash flow.
What is the current Forward P/E ratio for Salarius Pharmaceuticals Inc (SLRX) as of Jan 08 2026?
As of Jan 08 2026, Salarius Pharmaceuticals Inc (SLRX) has a Forward P/E ratio of -0.00. This means the market is willing to pay $-0.00 for every dollar of Salarius Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Salarius Pharmaceuticals Inc (SLRX) as of Jan 08 2026?
As of Jan 08 2026, Salarius Pharmaceuticals Inc (SLRX) has a Forward P/S ratio of 0.00. This means the market is valuing SLRX at $0.00 for every dollar of expected revenue over the next 12 months.